Christiane Amanpour, chief international anchor for CNN, announced yesterday on air that she received a diagnosis of ovarian cancer.

“I’ve had successful major surgery to remove it, and I’m now undergoing several months of chemotherapy for the very best possible long-term prognosis, and I’m confident,” Amanpour said in her announcement.

Amanpour, 63, is known for her coverage of international conflicts, though she has been off the air due to her diagnosis for the past four weeks. She will be anchoring Mondays through Wednesdays on CNN while undergoing months of chemotherapy, in addition to three weeks of off-air time starting at the end of June, according to a story on CNN.

“I’m telling you this in the interest of transparency, but in truth, really mostly as a shout-out to early diagnosis, to urge women to educate themselves on this disease to get all the regular screenings and scans that you can, to always listen to your bodies and, of course, to ensure that your legitimate medical concerns are not dismissed or diminished,” Amanpour said.

CNN Worldwide President Jeff Zucker issued a statement on Amanpour’s announcement. He wrote, “I want to applaud Christiane Amanpour for her candor, bravery and always working towards the greater good. As a cancer survivor, I, too, encourage people to listen to their bodies and get all early cancer screenings available to them. From our CNN family, we wish Christiane the very best for a full and speedy recovery.”

Right after her announcement on CNN, she was met by an outpouring of support online from her CNN colleagues including Chief White House Correspondent Kaitlan Collins: “Always in awe of (Christiane Amanpour), but especially today,” she wrote on Twitter. “Wishing her the best as she undergoes chemo. After letting viewers know she’s been diagnosed with ovarian cancer, she says, ‘So that’s my news. Now let’s get to the news.’”

Bianna Golodryga, CNN’s senior global affairs analysis who took Amanpour’s place in her recent absence, also tweeted about the news, writing, “(Christiane,) you’re not only one of the best journalists in the business, you’re also one of the toughest. Wishing you a speedy and healthy recovery in the weeks ahead. No doubt you’ll end up on top. It’s been a privilege helping you and your extraordinary team.”

Articles

Amanpour, who is CNN's chief international anchor, announced her diagnosis live on-air, while advocating for cancer screening, too. 

CNN Anchor Christiane Amanpour Reveals Ovarian Cancer Diagnosis

CURE Media Group recognized Maria Lim, BSN, RN, OCN, BMTCN, as the winner of its 2021 Extraordinary Healer® Award for Oncology Nursing, which honors the expertise, compassion, and helpfulness of nurses in the cancer community. 

In addition, Jennifer E. Giovanni, PhD, MSN, MPH, RN, received the Finest Hour Award, which recognizes the self- less achievements of a nurse caring for patients during the COVID-19 pandemic.

Essays were submitted by colleagues, patients, and family members that identified Lim, 2 finalists, and nearly 100 other Extraordinary Healer® nominees, all detailing the noble acts of oncology nurses. These ranged from providing a shoulder to cry on or a blanket to keep warm to making accommodations above and beyond the call of duty so that patients’ experiences during cancer treatment are a little more tolerable. Both awards were presented on April 29 during a virtual celebration held in conjunction with the 46th Annual Oncology Nursing Society Congress.

Lim, a nurse since 1993, moved from the Philippines to the United States and serves as a hematology/oncology/infusion clinic nurse at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois. She was nominated by one of her patients, who considers her the modern-day “angel of the battlefield.” Lim aims to be not only a nurse but a support system for all her patients, some of whom have battles beyond cancer, with posttraumatic stress disorder, for example.

Giovanni, who was previously a travel nurse, started her life of serving others in 1995 when volunteering with the Peace Corps. Since then, she has worked for several agencies, including the Centers for Disease Control and Prevention and the US Air Force. Most recently, she has worked in New York and New Jersey as a crisis response critical care nurse in areas severely affected by the COVID-19 pandemic.

Finalists for the Extraordinary Healer® award included Jessica Ellison, MSN, BA, RN, a transplant coordinator at Rush University Medical Center in Chicago, Illinois, and Katherine Gacek, BSN, RN, OCN, a nurse navigator from the University of Chicago Medicine in Illinois.

Mike Hennessy Jr, president and CEO of MJH Life SciencesTM, the parent company of CURE Media Group, mentioned that he had directly experienced the impact oncology nurses have. His mother, Patti Hennessy, died in January 2020 after living with breast and ovarian cancers for 9 years.

“The nominations come from your patients, your coworkers, and loved ones, and it’s just utterly remarkable,” Hennessy said. “After reading through the different essays we received and seeing firsthand the care that my mother received during her battles with cancer, it is clear that oncology nurses are the most selfless, caring, and truly inspiring individuals that you can be around. The way that you’re all able to comfort patients in what is probably the most traumatic time of their lives is galvanizing.”


Keynote speaker and award-winning actor and producer Sterling K. Brown, who is known for his role as Randall Pearson on the TV show This Is Us, among others, delved deeper into his role as a cancer advocate, which stemmed from his experience of losing his uncle to cancer.

During his keynote lecture, he showed his appreciation of oncology nurses, who often lean into the stressful, emotional situation rather than step away from it.

Maria Lim was nominated by her patient Bradford Evans, whom she has known for nearly 5 years. In his interview, Evans said he can’t imagine working with any other attending nurse and calls her the “helping hands” of the infusion unit.

“Myself or any of the other patients, we don’t know what tomorrow is going to hold,” Evans said. “It’s by the grace of God that we’re here. Ms Maria, through her helping hands, she’s the emissary of God, [who] keeps us alive and keeps us kicking. I will forever be indebted to her for her kindness, her professionalism. She listens to us, and not only me, but she listens to all the patients.”

Lim had an important role in his life the moment Evans received his cancer diagnosis. “As soon as he said, ‘[I’m referring you to] oncology,’ my world stopped, and she brought the world back around,” he said.

Lim aims to make chemotherapy a “somewhat enjoyable event,” by cheering patients up, Evans said. She greets them with a warm smile and even places patients near each other so they can share stories about their active duty days.

Lim has always recognized the importance of patients with cancer, especially those who are on active duty or are veterans. “When they’re diagnosed, it’s really like, OK, they’re veterans, they have this experience,” she said. “Some of them have PTSD, they have psych issues... and now they’re diagnosed with cancer. It’s like another battle for them.”

Jennifer E. Giovanni was nominated by her aunt, Pam Malone, RN, APRN, who quoted a previous writing by Giovanni in her nominating essay and interview. Malone mentioned how, from the start, Giovanni’s life has been one of serving others.

“Jennifer is someone who has done in her life all the things I wish I could have done,” Malone said. "From the get-go, even before she became a nurse, hers was a life of service and trying to help others, starting out in the Peace Corps and progressing from there. Most recently with [COVID-19], she has been on those front lines on more than 1 occasion. And I don’t know how she does it, but she did, and her experiences really meant a lot to her.”

During the interview, Giovanni described a time she was there for a patient who had stage 4 lung cancer with metastases to his brain and liver before he was intubated, which required “one final call” with his wife and children. With an iPad in hand, Giovanni brought his family to his bedside virtually. The patient’s family comforted him, saying “Don’t worry” and “We’ll see you in a little bit,” although he understood his outcome. The patient’s son came to visit the day before his father died.

“I was in there cleaning the room and doing those herculean nursing tasks that we all have to do somehow in 14 hours,” Giovanni said. “The son was outside the room, and I just thought what it must be like to stand there and look at your father intubated, clearly in a bad way, and not be able to touch [him]...That was a heavy day, but that was also a heavy phone call, but also one that I walked away from with gratitude because I was that presence at that sacred space.”

Giovanni took the opportunity to thank everyone for the award not only for herself, but also on behalf of all nurses on the front lines. “There’s something very special about the nurses that came forward to take care of patients with severe COVID-19, and also those that keep doing it day after day after day,” she said. “The trauma of it is profound, and it doesn’t come upon [us] until one steps away, and then it is overwhelming. I worry about the nurses that are out there doing this day in and day out. They are the true heroes.”

Jessica Ellison was nominated by Paul Kent, MD, from Rush University Medical Center, who credits her for establishing their institution as a national leader for patients with fibrolamellar carcinoma, a liver cancer that typically affects healthy adolescents and young adults.

“We have 2 of the best surgeons you could ever want, the best interventional radiologist you ever want, but not a single part of this, not from day 1 and not until today, would have been possible without Jessica,” Kent said during the interview.

Ellison mentioned that she was at first caught off guard when she received a
phone call saying she was a finalist for the Extraordinary Healer®, but then realized that Kent must have nominated her for it. “It has been a lot of work,” she said about establishing the program at her institution. “There’s been a lot of...tears from my eyes, tears from the patients’ eyes. It’s been a long journey for all of us, but in the end, I know that some of the work or all of the work that I have done has helped several patients, families, and their caregivers.”

Katherine Gacek was nominated by Rose Conti, MSN, RN, CNM, who described in her essay and interview about a time the nurse navigator made a storyboard to detail every treatment step for a nonverbal patient with autism who was being treated for Hodgkin lymphoma. The patient, who at first had disruptive behavior because he did not under- stand the severity of disease, was put at ease through Gacek’s efforts.

“She does this for all of her patients, but this patient in particular was [one] who stood out,” Conti said in the interview. “Her extra steps to care for this patient and make him feel comfortable did just so. It was a world of difference [between] what we saw in his actions and how he actually took his care while he was with us.”

“I could not believe that it worked so well,” Gacek said. “And I just feel like I had such a small piece of the puzzle to get this done, but I think it just showed that sometimes we have to think outside of the box. That was one of those cases, and nurses are doing all these things all the time. We’re being very inventive, and it’s not always straightforward, but we just have to find a way to get things done.”

Gacek noted how recognition, such as being an Extraordinary Healer® finalist, is a humbling experience.

“I’m just so, so thankful that nurses are being recognized, because there are times
that we are the unsung heroes,” she said. “Especially in oncology, we wear so many hats, and along with helping patients get through their treatment, that means so many things. That could mean helping with side effects or helping someone get to and from their appointments or helping a mom explain to their school-aged child what it means to go through chemotherapy and what that is going to mean for them. It’s just such a rewarding experience already, [and I feel] so appreciated to get recognized.”

Kristie L. Kahl, vice president of content at MJH Life Sciences

, the parent company of CURE Media Group, hosted the virtual event. She took the opportunity to thank the nurses and doctors who have worked tirelessly throughout the COVID-19 pandemic.

“I would like to thank all the front-line nurses and doctors who have not skipped a beat,” she said. “Over the last year plus, you’ve put your health and the health of your family members at risk, all to ensure that your patients can continue their treatments and now get vaccinated against this virus that has turned our worlds upside down. Your dedication has not gone unnoticed. Your patients thank you, we thank you, and we hope everyone continues to stay safe.”

Bristol Myers Squibb and Janssen Oncology sponsored the event. Jana Low, regional business director Bristol Myers Squibb, experienced the selflessness of oncology nurses when she herself received a diagnosis of melanoma.

“On behalf of everyone at Bristol Myers Squibb, I thank you for your compassion,
your dedication, and for being there every day for each of us. No matter what nurse hat you’re wearing, you are critical in our fight. Each battle is unique to that [patient] and their family, and through your work, continue giving patients and their loved ones the strength when they need it most,” Low said.

Pearl Pugh, vice president of sales and marketing in hematology at the Janssen Pharmaceutical Companies of Johnson & Johnson, said the COVID-19 pandemic has been a challenge for everyone but especially front-line workers, who dedicate their lives to others despite the circumstances.

“During the pandemic, when patients have not been able to have their loved ones or care- givers by their sides in the hospital or at treatment clinics, you’ve helped to fill the void by offering hope and support,” Pugh said.

Laura Leonetti, director of marketing (brand lead) of hematology and oncology at Janssen Oncology, echoed Pugh’s admiration of front- line workers during the COVID-19 pandemic.

“The COVID-19 pandemic has put the role of front-line health care workers, including nurses like yourselves, in the well-deserved spotlight,” Leonetti said. “For over a year now, you have overcome tremendous challenges and worked tirelessly during an unprecedented health care crisis. The world has seen first- hand the skill, determination, and heart it takes to serve as a nurse on the front lines. You are truly bright and brave heroes, not only to cancer patients but to all of us.”

CURE Media Group also recognized Jennifer E. Giovanni, PhD, MSN, MPH, RN, as winner of the Finest Hour Award, which highlights the dedi- cation and selflessness exhibited in frontline workers during the COVID-19 pandemic.

Maria Lim, BSN, RN, OCN, BMTCN, Wins CURE's 2021 Extraordinary Healer for Oncology Nursing

In states with more restrictive Medicaid eligibility, patients with cancer tended to have poorer long-term outcomes than those with higher income limits to qualify. Findings from this study were presented in a media webcast before the 2021 ASCO Annual Meeting.

“Policies to increase Medicaid income eligibility limits such as Medicaid expansion may help improve survival following cancer diagnosis,” Jingxuan Zhao, MPH, associate scientist with the American Cancer Society, said during the webcast.

Income eligibility limits for Medicaid varies substantially by state for non-elderly patients, according to the presentation. For example, the federal poverty line for a family of four in 2009 was $22,050. The Medicaid eligibility limit was 27% of the federal poverty line in Texas, whereas this limit was 150% for New York.

With this study, researchers aimed to assess the associations between state Medicaid income eligibility limits and long-term survival in patients with newly diagnosed cancer. This was analyzed with data from an estimated 1.5 million adults from the National Cancer Database aged 18 to 64 years who were newly diagnosed with 17 common cancers between 2010 and 2013. Patients were followed up through the end of 2017 for up to 8 years of follow-up.

State Medicaid income eligibility limits were categorized as less than 50% of the federal poverty line, between 51% and 137% of the federal poverty line and greater than 138% of the federal poverty line.

When patients with all cancer types were combined, patients who lived in states with the low Medicaid income eligibility limits had the worst survival rates compared with those who lived in states with high limits. This was seen for patients with stages 1 and 2 cancers and in those with stages 3 and 4 cancers.

Similar findings were observed when data were categorized by cancer type. For example, compared with states with eligibility limits greater than 138%, women with stage 1 and 2 breast cancer in states with a limit less than 50% (adjusted HR = 1.31; 95% CI, 1.18-1.46) and limits between 51% and 137% (adjusted HR = 1.17; 95% CI, 1.06-1.3) had worse long-term survival. This was also seen in women with stage 3 and 4 breast cancer (adjusted HR for less than 50% = 1.21; 95% CI, 1.1-1.33; adjusted HR for 51% to 137% = 1.13; 95% CI, 1.03-1.23).

Researchers also observed similar findings for other common cancers including prostate, colorectal and non-small cell lung cancers.

“[These findings are] particularly relevant … since there [are] such variable limits among states regarding Medicaid expansion with the [Affordable Care Act],” Lori J. Pierce, MD, FASTRO, FASCO, radiation oncologist, professor and Vice Provost for Academic and Faculty Affairs at the University of Michigan in Ann Arbor and director of the Michigan Radiation Oncology Quality Consortium, said during the discussion after the presentation. “I think these data can be used to encourage those states who have chosen not to expand Medicaid coverage to strongly reconsider because people who are uninsured are very likely to forego screening, so you miss the detection of early lesions where cure would be far more likely. Those who are uninsured are unlikely to receive cancer care. And for those who are able to start cancer treatment, they're unlikely to complete their cancer care. Equity of care is very, very critical.”

Zhao J, et al. Association of State Medicaid Income Eligibility Limits and Long-Term Survival After Cancer Diagnosis in the United States. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 6512.

States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research. 

Restrictive Medicaid Eligibility May Negatively Impact Cancer Survival

A lifestyle medicine clinic led by an advanced practice nurse and a dietician helped patients with a history of cancer learn more about health behaviors to potentially improve outcomes, according to a virtual poster presentation at the Oncology Nursing Society Congress.

“An oncology advanced practice nurse and dietician-led lifestyle medicine clinic really complements the standard cancer follow-up visit by expanding upon evidence-based health behaviors counseling to empower patients and improve outcomes,” Loren Winters, MSN, ANP-BC, OCN, oncology nurse practitioner at Massachusetts General Hospital Cancer Center, said during the presentation.

A third of all cancer cases in the United States are linked to diet and lifestyle, and an estimated 70% of all cancer survivors in this country are overweight or obese, according to the presentation. Diet and lifestyle counseling are a component of national guidelines for cancer prevention.

“Oncology nurses within the oncology care team share a key role in providing cancer-specific, evidence-based information and resources to aid in recovery after cancer treatment as well as to promote health behaviors,” Winters said during her presentation. “Typical cancer follow-up visits are time limited and often do not allow for a comprehensive lifestyle behaviors assessment and counseling.”

With the help of Carol Sullivan, MS, RD, CSO, LDN, senior clinical nutritionist at Massachusetts General Hospital Cancer Center, Winters and the lifestyle medicine multidisciplinary team at her institution created a program for patients with a history of cancer. The program was predominantly led by an advanced practice oncology nurse and an oncology registered dietician.

Once patients are referred to this program by their cancer team, they underwent consultations focused on education and motivation. These consultations emphasized the importance of a whole food plant-forward diet, restorative sleep, regular physical activity, avoidance of risky substances, stress management and positive social connections. Based on needs, patients had free access to webinars, exercise videos and referrals to other specialists or supportive care programs. All of these visits are now conducted through telehealth platforms due to the COVID-19 pandemic.

Winters and Sullivan received some insightful feedback on the program including that it had an empowering effect on them and it was specifically tailored to their needs.

“Future directions include shared medical or group visits to improve the patient experience by providing an interactive setting in which patients can learn and inspire each other to adopt lasting health behavior change,” Winters said during her presentation.

Winters L, Sullivan C. An Advanced Practice Nurse and Registered Dietitian Led Lifestyle Medicine Clinic. Presented at: the Oncology Nursing Society 46th Annual Congress. April 20, 22, 27, 29, 2021.

A clinic for patients with a history of cancer led by an advanced practice nurse and a dietician may empower patients to improve their lifestyles through diet and exercise, especially since it may have an impact on their outcomes and future risk for diseases.

Lifestyle Medicine Clinic May Help Cancer Survivors Improve Their Diet, Physical Activity

Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision, according to results from a study presented at the 2020 World Conference on Lung Cancer Singapore.

In addition, few patients reported feeling prepared to discuss options with their doctors, and many patients wanted more support prior to making a treatment decision, according to a virtual presentation on the findings.

“With recent advances in early detection of lung cancer, biomarker testing and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA, research manager at the Research and Training Institute at Cancer Support Community in Philadelphia, during the presentation. “Open communication between patients and clinicians about treatment options and cancer experience is a critical step toward collaborative treatment decision making.”

Researchers assessed responses from 276 patients (mean age, 61.8 years; 67% women; 86% White) with lung cancer in the Cancer Support Community’s Cancer Experience Registry, “an online survey open to any adult ever diagnosed with cancer,” Clark explained. Patients in this study answered additional questions about their lung cancer diagnosis and treatment decision making.

Of the patients in this study, 82% had non-small cell lung cancer. The mean time since diagnosis for all patients was three years. In addition, 23% had cancer recurrence and 39% had metastatic cancer. With regards to treatment, 76% underwent chemotherapy and 28% received immunotherapy. More than half of the patients in this study — 58% &mdash; were currently undergoing treatment.

With regards to treatment decision making, 67% of patients reported that they were quite a bit, or very much, involved in the process compared to 33% who reported they were somewhat or not at all involved. In addition, 34% reported being quite a bit or very knowledgeable about their treatment options before going through the treatment decision-making process versus 66% who were somewhat or not at all knowledgeable about their options.

Findings also determined that 38% of patients would have liked more support before treatment decision making compared with 42% who did not feel that they needed more support. Sixty percent of patients were somewhat or not at all prepared to discuss treatment options with their doctor compared with 40% who reported they were quite a bit or very much prepared to do so.

Preparation to discuss treatment options with the doctor was positively correlated with involvement in the treatment decision-making process (r = .52; P < .001) and knowledge about treatment options (r = .51; P < .001). Patients with income greater than $40,000 were more likely to be more prepared, have more knowledge about treatment options and were more involved in the treatment decision-making process compared with those with an income less than $40,000.

“(This is) suggesting that those with lower income may have less access to treatment decision-making resources compared to their economically advantaged counterparts,” said Clark during the presentation.

There was a small yet statistically significant difference regarding sex and preparation for treatment option discussions with their doctor. Women were more likely than men to report feeling prepared for these discussions (t = 2.69; P < .01). In contrast, treatment decision-making factors did not differ by race, age and lung cancer subtype.

“Results suggest involvement alone is insufficient for an informed treatment decision-making experience and highlight a need for additional resources such as treatment decision-making guides or in-person counseling to enhance health care team communication surrounding treatment decision making for individuals with lung cancer, particularly for economically disadvantaged individuals. Such efforts may provide patients better knowledge about treatment options, thus enhancing their preparation to discuss and select the appropriate treatment pathway,” Clark concluded.

Kranzler EC, Fortune EE, Miller MF, et al. Treatment Decision-Making and Decisional Support Experiences Among Lung Cancer Patients and Survivors. Presented at: 2020 World Conference on Lung Cancer Singapore; January 28-31, 2021; virtual. Abstract FP06.02.

This article was originally published on OncLive as, "

Clinicians May Need to Further Educate Their Patients About Treatment Options During Decision-Making Process

Patients Need Better Treatment Education, Study Finds

Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

Stage 4 gastrointestinal stromal tumors, although a rare cancer, commonly starts in the small intestine and stomach in men, according to a poster presented at the virtual ASCO Gastrointestinal Cancers Symposium.

In addition, patients frequently had hepatic metastases and great overall survival at 5 years, according to the poster.

“Combined surgery [and] systemic therapy demonstrates best outcomes, although surgical resection alone might yield comparable results in selected patients,” the Johannes Uhlig, MD, MPH, resident in the department of diagnostic and interventional radiology at University Medical Center Goettingen in Denmark and visiting researcher in the department of radiology and biomedical imaging at Yale School of Medicine and colleagues wrote in the abstract.

To assess the epidemiology, treatment and outcomes of patients with stage 4 gastrointestinal stromal tumors, researchers queried data from the United States National Cancer Database from 2010 to 2016. This analysis focused on 1,578 patients with invasive stage 4 gastrointestinal stromal tumors without prior malignant disease.

The number of patients in this study represented 13.3% of all patients with gastrointestinal stromal tumors. The men-to-women ratio of these patients was 1.38:1. Patients were diagnosed with gastrointestinal stromal tumors at a median age of 62 years with a median tumor diameter of 10 cm. Most patients had cancer in the stomach (55.4%) and small intestine (40%). More than half of the patients had distant organ metastases (58.7%), with the most common being hepatic, occurring in 50.8% of patients.

Most patients were treated with systemic therapy (78.6%) either combined with surgery (43.3%) or alone (35.4%). For patients who underwent surgical resection, 6.9% received neoadjuvant systemic therapy, 32% received adjuvant therapy and 5.1% received a combination of both. In addition, 12.9% of patients underwent surgical resection alone.

Overall survival rates for patients with gastrointestinal stromal tumors were 88% at 1 year, 77% at 2 years, 67% at 3 years and 51% at 5 years.

Based on multivariable Cox proportional hazard models, researchers found that primary treatment for gastrointestinal stromal tumors independently affected overall survival. Patients had shorter overall survival when treated with systemic therapy alone (HR = 2.77; 95% CI, 2.12-3.61; P < .001) or no treatment (HR = 4.2; 95% CI, 2.75-6.43; P < .001) compared to treatment with surgery and systemic therapy. The difference in overall survival was not significant when patients treated with surgery and systemic therapy were compared with surgery alone (HR = 1.23; 95% CI, 0.88-1.72; P = .227). Overall survival was not statistically different when neoadjuvant, adjuvant and combined neoadjuvant and adjuvant systemic therapy was compared in subgroup analyses of patients who underwent surgical resection.

Patients treated at nonacademic centers had shorter overall survival compared with those treated at academic centers (multivariable HR = 1.36; 95% CI, 1.1-1.69; P = .005). Other independent predictors of overall survival included older age, men (vs. women; HR = 1.28; 95% CI, 1.03-1.59; P = .023), higher cancer grade, higher comorbidities and large cancer diameter.

Uhlig J, Stein S, Lacy J, et al. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Presented at: 2021 ASCO Gastrointestinal Cancers Symposium; January 15-17, 2021; virtual. Abstract 462.

Invasive Gastrointestinal Stromal Tumors More Common in Men, Initiating in the Small Intestine and Stomach